Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate ... patients to double the dose of their inhaled corticosteroid medication for a ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

big-selling respiratory drug Seretide in the UK. Seretide (salmeterol xinafoate/fluticasone propionate) – sold as Advair in the US and other markets – is the top-selling inhaled beta agonist ...

Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...

We assessed socioeconomic covariates (mean copayments, total copayments, and unique brand-to-generic prescription fills ... with people receiving budesonide-glycopyrrolate-formoterol. Dry powder ...

a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score ...

The researchers found that dry powder triple inhaler therapy of fluticasone-umeclidinium-vilanterol resulted in fewer COPD exacerbations compared to metered dose triple inhaler therapy of ...

Mylan has launched its generic version ... The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired in 2016.

30 in The BMJ. William B. Feldman, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a ...